Teachers Retirement System of The State of Kentucky Acquires 8,528 Shares of Eli Lilly and Company (NYSE:LLY)

Teachers Retirement System of The State of Kentucky grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 8.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 107,040 shares of the company’s stock after buying an additional 8,528 shares during the quarter. Eli Lilly and Company accounts for about 0.7% of Teachers Retirement System of The State of Kentucky’s investment portfolio, making the stock its 14th biggest position. Teachers Retirement System of The State of Kentucky’s holdings in Eli Lilly and Company were worth $82,635,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Principal Financial Group Inc. raised its position in shares of Eli Lilly and Company by 5.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock worth $1,070,698,000 after acquiring an additional 60,306 shares in the last quarter. M&T Bank Corp grew its position in Eli Lilly and Company by 0.7% during the third quarter. M&T Bank Corp now owns 266,822 shares of the company’s stock valued at $236,389,000 after buying an additional 1,867 shares during the period. Invst LLC grew its stake in Eli Lilly and Company by 3.5% in the 3rd quarter. Invst LLC now owns 5,552 shares of the company’s stock valued at $4,918,000 after acquiring an additional 189 shares during the period. McIlrath & Eck LLC raised its position in Eli Lilly and Company by 3.4% during the third quarter. McIlrath & Eck LLC now owns 481 shares of the company’s stock worth $426,000 after acquiring an additional 16 shares during the period. Finally, Virtu Financial LLC grew its position in shares of Eli Lilly and Company by 111.7% in the third quarter. Virtu Financial LLC now owns 6,531 shares of the company’s stock valued at $5,786,000 after purchasing an additional 3,446 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.14% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Truist Financial raised their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. The Goldman Sachs Group raised Eli Lilly and Company from a “neutral” rating to a “buy” rating and cut their price objective for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Morgan Stanley reduced their price target on shares of Eli Lilly and Company from $1,146.00 to $1,124.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 9th. Finally, Berenberg Bank set a $970.00 target price on shares of Eli Lilly and Company in a report on Thursday, January 16th. Two equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,012.00.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $841.70 on Friday. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The firm has a fifty day simple moving average of $829.09 and a 200-day simple moving average of $819.86. The stock has a market capitalization of $798.08 billion, a price-to-earnings ratio of 71.88, a PEG ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.